Try a new search

Format these results:

Searched for:



Total Results:


Expression of cancer-testis (CT) antigens in placenta

Jungbluth, Achim A; Silva, Wilson A Jr; Iversen, Kristin; Frosina, Denise; Zaidi, Bushra; Coplan, Keren; Eastlake-Wade, Susannah K; Castelli, Sandra B; Spagnoli, Giulio C; Old, Lloyd J; Vogel, Martin
Besides their variable presence in fetal and adult germ cells, CT antigens have occasionally been detected in placental tissue. However, these data are scarce and solely based on mRNA analyses; nothing is known about their presence at the protein level. Here, we analyzed the expression of various CT antigens in placental tissues from gestational age week 5 to week 42 using monoclonal antibodies to various antigens of the MAGE-A and -C families, NY-ESO-1, as well as GAGE. We show that CT antigen expression in placenta varies widely for the various antigens, ranging from completely negative to abundant. Since little is known about the function and biology of CT antigens, interpretation of this highly variable expression pattern is purely speculative. However, our data indicate that the various CT antigens have different functions during placental development
PMID: 17715884
ISSN: 1424-9634
CID: 144891

NY-BR-1 is a differentiation antigen of the mammary gland

Jager, Dirk; Filonenko, Valeriy; Gout, Ivan; Frosina, Denise; Eastlake-Wade, Susannah; Castelli, Sandra; Varga, Zsuzsanna; Moch, Holger; Chen, Yao-Tseng; Busam, Klaus J; Seil, Inka; Old, Lloyd J; Nissan, Aviram; Frei, Claudia; Gure, Ali O; Knuth, Alexander; Jungbluth, Achim A
NY-BR-1 was recently identified by autologous serological typing of the recombinant expression library in a breast cancer patient. Extensive reverse transcriptase-polymerase chain reaction analysis revealed the presence of NY-BR-1 in normal breast tissue and tumors derived thereof. Except normal testis, no other normal tissue or tumors showed NY-BR-1 expression. However, nothing is known about the expression of its actual antigen. In the present study, we describe the generation of 2 new monoclonal antibodies, NY-BR-1#2 and NY-BR-1#3, to NY-BR-1 for the analysis of its expression on a protein level employing recombinant NY-BR-1 protein for the immunization of BALB/c mice. In normal tissues, immunohistochemical testing demonstrates NY-BR-1 in a mostly focal fashion in the epithelia of ducts and acini of the mammary gland. No other tissue was immunopositive including testis. In tumors, homogenous staining can be seen in almost all ductal carcinomas in situ and/or the intraductal component of invasive carcinomas. Invasive carcinomas show a lower number of NY-BR-1-positive tumors. Initial higher numbers of NY-BR-1 mRNA-positive invasive carcinomas are most likely based on sample error owing to the contamination of tumor tissue with remnants of normal breast epithelium. Sweat gland carcinomas, which are related to breast cancer, are also positive in about one-third of the cases. These data indicate that NY-BR-1 is a differentiation antigen of the mammary gland that could be useful for diagnosis and/or immunotherapy of breast carcinomas
PMID: 17536312
ISSN: 1541-2016
CID: 144904